-DOCSTART- -X- O
Spinal -X- _ B-Patient
muscular -X- _ I-Patient
atrophy -X- _ I-Patient
( -X- _ I-Patient
SMA -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
the -X- _ O
leading -X- _ O
genetic -X- _ O
cause -X- _ O
of -X- _ O
infant -X- _ O
mortality -X- _ O
, -X- _ O
is -X- _ O
caused -X- _ O
by -X- _ O
reduced -X- _ O
levels -X- _ O
of -X- _ O
functional -X- _ O
survival -X- _ O
motor -X- _ O
neuron -X- _ O
( -X- _ O
SMN -X- _ O
) -X- _ O
protein. -X- _ O
To -X- _ O
identify -X- _ O
therapeutic -X- _ O
agents -X- _ O
for -X- _ O
SMA -X- _ O
, -X- _ O
we -X- _ O
established -X- _ O
a -X- _ O
versatile -X- _ O
SMN2-GFP -X- _ O
reporter -X- _ O
line -X- _ O
by -X- _ O
targeting -X- _ O
the -X- _ O
human -X- _ O
SMN2 -X- _ O
gene. -X- _ O
We -X- _ O
then -X- _ O
screened -X- _ O
a -X- _ O
compound -X- _ B-Intervention
library -X- _ I-Intervention
and -X- _ O
identified -X- _ B-Outcome
Z-FA-FMK -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
potent -X- _ I-Outcome
candidate. -X- _ I-Outcome
Z-FA-FMK -X- _ O
, -X- _ O
a -X- _ O
cysteine -X- _ O
protease -X- _ O
inhibitor -X- _ O
, -X- _ O
increased -X- _ O
functional -X- _ O
SMN -X- _ O
through -X- _ O
inhibiting -X- _ O
the -X- _ O
protease-mediated -X- _ O
degradation -X- _ O
of -X- _ O
both -X- _ O
full-length -X- _ O
and -X- _ O
exon -X- _ O
7–deleted -X- _ O
forms -X- _ O
of -X- _ O
SMN. -X- _ O
Further -X- _ O
studies -X- _ O
reveal -X- _ O
that -X- _ O
CAPN1 -X- _ B-Outcome
, -X- _ I-Outcome
CAPN7 -X- _ I-Outcome
, -X- _ I-Outcome
CTSB -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
CTSL -X- _ I-Outcome
mediate -X- _ I-Outcome
the -X- _ I-Outcome
degradation -X- _ I-Outcome
of -X- _ I-Outcome
SMN -X- _ I-Outcome
proteins -X- _ I-Outcome
, -X- _ I-Outcome
providing -X- _ I-Outcome
novel -X- _ I-Outcome
targets -X- _ I-Outcome
for -X- _ I-Outcome
SMA. -X- _ I-Outcome
Notably -X- _ O
, -X- _ O
Z-FA-FMK -X- _ O
mitigated -X- _ O
mitochondriopathy -X- _ O
and -X- _ O
neuropathy -X- _ O
in -X- _ O
SMA -X- _ O
patient–derived -X- _ O
motor -X- _ O
neurons -X- _ O
and -X- _ O
showed -X- _ O
protective -X- _ O
effects -X- _ O
in -X- _ O
SMA -X- _ O
animal -X- _ O
model -X- _ O
after -X- _ O
intracerebroventricular -X- _ O
injection. -X- _ O
E64d -X- _ B-Outcome
, -X- _ I-Outcome
another -X- _ I-Outcome
cysteine -X- _ I-Outcome
protease -X- _ I-Outcome
inhibitor -X- _ I-Outcome
which -X- _ I-Outcome
can -X- _ I-Outcome
pass -X- _ I-Outcome
through -X- _ I-Outcome
the -X- _ I-Outcome
blood–brain -X- _ I-Outcome
barrier -X- _ I-Outcome
, -X- _ I-Outcome
showed -X- _ I-Outcome
even -X- _ I-Outcome
more -X- _ I-Outcome
potent -X- _ I-Outcome
therapeutic -X- _ I-Outcome
effects -X- _ I-Outcome
after -X- _ I-Outcome
subcutaneous -X- _ I-Outcome
delivery -X- _ I-Outcome
to -X- _ I-Outcome
SMA -X- _ I-Outcome
mice. -X- _ I-Outcome
Taken -X- _ O
together -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
successfully -X- _ O
established -X- _ O
a -X- _ O
human -X- _ O
SMN2 -X- _ O
reporter -X- _ O
for -X- _ O
future -X- _ O
drug -X- _ O
discovery -X- _ O
and -X- _ O
identified -X- _ O
the -X- _ O
potential -X- _ O
therapeutic -X- _ O
value -X- _ O
of -X- _ O
cysteine -X- _ O
protease -X- _ O
inhibitors -X- _ O
in -X- _ O
treating -X- _ O
SMA -X- _ O
via -X- _ O
stabilizing -X- _ O
SMN -X- _ O
proteins -X- _ O
. -X- _ O

